Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Kura Oncology, Inc.NASDAQ: KURA
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 384.6% from a year ago
Other current liabilities stood at $34.76M at the end of Q1 FY2026, up 384.6% from a year earlier and down 11.1% from the prior quarter. Over 3 fiscal years it compounded at +29.5% a year.
Context
- Other current liabilities amounted to 5.3% of total assets at the end of Q1 FY2026, up 4.4 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +384.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 22.37M USD
- Year-over-year change
- +27.8%
- 4-year CAGR
- +29.6%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.37M | +27.8% |
| FY2024 | 2024-12-31 | 17.51M | +33.1% |
| FY2023 | 2023-12-31 | 13.15M | +27.7% |
| FY2022 | 2022-12-31 | 10.3M | +30.0% |
| FY2021 | 2021-12-31 | 7.92M | — |
Other Current Liabilities vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's Mar 2026 other current liabilities of $34.76M is the 3rd highest of the 11 companies compared; the peer median is $15.66M.
- Its year-over-year change of +384.6% is the 2nd highest of 10, against a peer median of +22.8%.
- Other current liabilities amounts to 5.3% of total assets for KURA, versus a peer median of 3.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $240.31M | -17.2% | +67.9% | 13.7% | |
| Mar 2026 | $48.5M | +42.8% | +51.7% | 9.6% | |
| Mar 2026 | $34.76M | +384.6% | +29.5% | 5.3% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $28.61M | +399.3% | — | 6.9% |
| Aug 2026 | $22.23M | +22.8% | +37.3% | 1.9% | |
| Mar 2026 | $18.2M | -30.4% | +150.6% | 3.9% | |
| Mar 2026 | $13.11M | — | — | 3.2% | |
| Mar 2026 | $7.91M | +146.3% | +74.6% | 3.5% | |
| Mar 2026 | $4.53M | +248.6% | +9.5% | 9.2% | |
| Mar 2026 | $3.8M | -5.1% | +29.6% | 0.9% | |
| Sep 2026 | $0 | -100.0% | -31.4% | 0.0% | |
| Peer median (excluding KURA) | $15.66M | +22.8% | +44.5% | 3.7% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 90.67M | 51.8M | 37.32M | 224.46M | 149.1M |
| Short-term Investments | 427.29M | 386.18M | 386.64M | 502.93M | 518.14M |
| Net Receivables | 0 | 0 | 0 | 0 | 12.6M |
| Inventory | 0 | 0 | 0 | 0 | 413K |
| Other Current Assets | 1.4M | 8.44M | 8.52M | 17.43M | 28.41M |
| Total Current Assets | 522.29M | 446.43M | 432.48M | 744.83M | 708.66M |
| Property, Plant & Equipment (Net) | 8.25M | 6.38M | 8.85M | 7.49M | 15.16M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.52M | 3.5M | 7.6M | 7.85M | 14.54M |
| Total Non-current Assets | 11.76M | 9.88M | 16.45M | 15.33M | 29.7M |
| Total Assets | 534.05M | 456.31M | 448.94M | 760.16M | 738.36M |
| Account Payables | 3.24M | 1.53M | 2.3M | 1.47M | 5.02M |
| Short-term Debt | 0 | 0 | 0 | 2.61M | 0 |
| Tax Payables | 0 | 0 | 0 | 2.06M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 24.27M | 48.98M |
| Other Current Liabilities | 7.92M | 10.3M | 13.15M | 17.51M | 22.37M |
| Total Current Liabilities | 22.46M | 24.06M | 35.26M | 78.71M | 116.97M |
| Long-term Debt | 0 | 9.16M | 9.33M | 6.92M | 9.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 253.91M | 424.91M |
| Other Non-current Liabilities | 375K | 265K | 705K | 1.8M | 3.16M |
| Total Non-current Liabilities | 4.99M | 11.97M | 16.4M | 267.81M | 447.25M |
| Total Liabilities | 27.44M | 36.03M | 51.66M | 346.52M | 564.23M |
| Common Stock | 7K | 7K | 7K | 8K | 9K |
| Retained Earnings | (432.97M) | (568.81M) | (721.44M) | (895.42M) | (1.17B) |
| Accumulated OCI | (1.79M) | (8.03M) | (1.27M) | 764K | 1.02M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 506.61M | 420.28M | 397.27M | 413.64M | 174.14M |
| Total Debt | 6.88M | 14.02M | 17.2M | 16.59M | 20.46M |
| Net Debt | (83.8M) | (37.78M) | (20.12M) | (207.87M) | (128.64M) |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.